MobiHealth News December 2, 2022
A GSR Ventures survey of 50 investors reveals return on investment and clinical validation would be vital to a company’s success next year.
Return on investment and clinical validation will be the most significant indicators for success for digital health companies in 2023, according to a survey by investment firm GSR Ventures.
The survey, which included responses from more than 50 investors, found that more than 94% deemed ROI to be “important” or “very important” to a digital health company’s success, and 79% said clinical evidence and trials were top indicators.
Investors anticipate digital health funding in 2023 will be between $15 billion and $25 billion. They also expect valuations will decrease by around 20% for seed stage funding....
Today's Sponsors
Today's Sponsor